论文部分内容阅读
美国密西根Wayne州大学Michael L.Cher博士和他的同事们报道说:在前列腺癌患者的癌细胞中,参与骨转换的基质金属蛋白酶(MMPs)极度活跃。 在美国国家癌症研究者杂志1月第2期中,他们报道了将人类骨碎片植入小鼠并注射人类前列腺癌细胞,通过每天给予小鼠batimastat(一种MMP抑制剂)治疗,观察骨碎片与前列腺癌细胞变化的研究。 研究者发现抑制MMP活性可有效地防止骨的破坏,研究中没有给予batimastat治疗的小鼠移植骨碎片退化。 他们还发现了抑制这些酶的活性可以抑制在移植骨上的前列腺癌细胞生长,这可能与骨破坏活动有关。当MMPs被抑制时,肿瘤细胞增生从21％降到7％。
Michael L. Cher, Ph.D., University of Wayne, Michigan, USA, and colleagues report that matrix metalloproteinases (MMPs) involved in bone turnover are extremely active in cancer cells of prostate cancer patients. In the January 2 issue of the National Cancer Institute journal, they reported that human bone fragments were implanted into mice and injected with human prostate cancer cells. The mice were treated daily with batimastat (a MMP inhibitor) and bone fragments were observed Study on Prostate Cancer Cells. The researchers found that inhibition of MMP activity was effective in preventing the destruction of bones, and degeneration of bone fragments in mice that were not treated with batimastat in the study was degraded. They also found that inhibiting the activity of these enzymes can inhibit the growth of prostate cancer cells on the graft bone, which may be related to bone destruction. When MMPs were inhibited, tumor cell proliferation decreased from 21% to 7%.